Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Adaptimmune revenue
Adaptimmune's revenue is $178.0 million.
What is Adaptimmune's revenue?
- Adaptimmune's revenue growth from 2014 to 2024 is 21,479.64%.
- Adaptimmune has 452 employees, and the revenue per employee ratio is $393,876.
- Adaptimmune's peak quarterly revenue was $128.2M in 2024(q2).
- Adaptimmune peak revenue was $178.0M in 2024.
- Adaptimmune annual revenue for 2023 was 60.3M, 122.05% growth from 2022.
- Adaptimmune annual revenue for 2024 was 178.0M, 195.34% growth from 2023.
On this page
Zippi applies for you, and finds you a job.
Adaptimmune historical revenue
Adaptimmune's peak revenue was $178.0M in 2024. The peak quarterly revenue was $128.2M in 2024(q2).
Adaptimmune's revenue increased from $825.0k in 2014 to $178.0M currently. That's a 21,479.64% change in annual revenue.
Adaptimmune annual revenue
Adaptimmune annual revenue over time
| Fiscal year / year | Adaptimmune revenue |
|---|---|
| 2014 | $825,000 |
| 2015 | $9.0M |
| 2016 | $14.2M |
| 2017 | $37.8M |
| 2018 | $59.5M |
| 2019 | $1.1M |
| 2020 | $4.0M |
| 2021 | $6.1M |
| 2022 | $27.1M |
| 2023 | $60.3M |
| 2024 | $178.0M |
How accurately did Adaptimmune's revenue projections match actual performance?
Adaptimmune annual growth
Adaptimmune saw the greatest revenue growth in 2015, when revenue increased by 988.36%.
Adaptimmune had the lowest revenue growth in 2019, when revenue changed by -98.11%.
Adaptimmune annual growth rate over time
| Year | Adaptimmune growth |
|---|---|
| 2015 | 988%↑ |
| 2016 | 58%↑ |
| 2017 | 166%↑ |
| 2018 | 57%↑ |
| 2019 | -98%↓ |
| 2020 | 253%↑ |
| 2021 | 55%↑ |
| 2022 | 342%↑ |
| 2023 | 122%↑ |
| 2024 | 195%↑ |
Adaptimmune quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Adaptimmune quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2015 | - | - | - | $9.0M |
| 2016 | $2.9M | $328,328 | $2.4M | $8.5M |
| 2017 | $2.9M | $3.5M | $27.3M | $4.3M |
| 2018 | $8.2M | $9.0M | $40.8M | $1.5M |
| 2019 | - | $157,000 | $237,000 | $728,000 |
| 2020 | $761,000 | $502,000 | $1.2M | $1.5M |
| 2021 | $434,000 | $3.1M | $1.2M | $1.4M |
| 2022 | $3.6M | $5.5M | $7.0M | $11.0M |
| 2023 | $47.6M | $5.1M | $7.3M | $231,000 |
| 2024 | $5.7M | $128.2M | $40.9M | $3.2M |
Adaptimmune jobs nearby
Do you work at Adaptimmune?
Did Adaptimmune meet its revenue projections?
Adaptimmune financial information
| CEO | Adrian Rawcliffe (Ad) |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 452 |
| Date Founded | 2008 |
| Headquarters | Philadelphia, Pennsylvania |
| Number of Locations | 1 |
| Revenue | $178.0M |
| Net Income | -$165,456,000 |
| Gross Proft | $178.0M (2024) |
| PE Ratio | -9.09 |
| Tax Rate | -0.1% |
| Market Capitalization | $643.4M |
| Total Assets | $328,916,000 |
| Ticker | ADAP |
Adaptimmune jobs you might like
Adaptimmune financing
Adaptimmune received early financing of $3.5M on 2014-03-26.
| Series | Round size | Date |
|---|---|---|
| Grant | $3.5M | 03/2014 |
| Series A | $104M | 09/2014 |
| Post Ipo Equity | $42M | 04/2017 |
| Post Ipo Equity | $100M | 09/2018 |
| Post Ipo Equity | $150M | 09/2021 |
Adaptimmune investors
| Investors | Security type |
|---|---|
| Biomedical Catalyst Fund | Grant |
| RIDGEBACK CAPITAL MANAGEMENT | Series A |
| Novo Holdings A | Series A |
| New Enterprise Associates (NEA) | Series A |
| QVT Financial LP | Series A |
| University of Oxford | Series A |
| Wellington Management | Series A |
| OrbiMed Advisors | Series A |
| Foresite Capital | Series A |
| venBio Partners | Series A |
| Merlin Nexus | Series A |
| F-Prime Capital | Series A |
| Rock Springs Capital | Series A |
| Genentech | Post Ipo Equity |
Adaptimmune competitors
Adaptimmune's top competitor, Regeneron, earned an annual revenue of $14.2B.
Adaptimmune's smallest competitor is GITR with revenue of $680.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Minerva Biotechnologies | - | $2.4M | 24 | - |
| TCR² Therapeutics | - | $661.1M | 118 | - |
| GITR | - | $680,000 | 12 | - |
| Refuge Biotechnologies | - | $11.0M | 175 | - |
| Arcellx | - | $107.9M | 1 | - |
| Regeneron | - | $14.2B | 9,123 | - |
| Exelixis | - | $2.2B | 484 | - |
| SDIX, LLC Marketing | - | $391.8M | 200 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Adaptimmune highest paying jobs
Zippia gives an in-depth look into the details of Adaptimmune, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Adaptimmune. The employee data is based on information from people who have self-reported their past or current employments at Adaptimmune. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Adaptimmune. The data presented on this page does not represent the view of Adaptimmune and its employees or that of Zippia.
Adaptimmune may also be known as or be related to ADAPTIMMUNE THERAPEUTICS PLC, Adaptimmune, Adaptimmune LLC, Adaptimmune Limited, Adaptimmune Ltd and Adaptimmune Therapeutics PLC.